- cafead   Jan 24, 2022 at 10:22: AM
via MaaT Pharma is racing its microbiome therapy into a late-phase cancer clinical trial. Rather than take the current phase 1b to its planned conclusion, MaaT is wrapping the trial up early to accelerate its push into a larger study of acute myeloid leukemia (AML) patients.
article source
article source